Introduction
============

*Rhodococcus equi* (*Rhodococcus hoagii/Prescottella equi*) is an important equine pathogen leading to a high mortality rate in newborn foals, thereby exerting a major financial impact on the equine industry ([@B32]). This gram-positive facultative intracellular bacterium causes severe pyogranulomatous pneumonia, as well as other less frequent clinical conditions, such as ulcerative enterocolitis and mesenteric lymphadenopathy ([@B10]). Mortality rates for *R. equi*-infected untreated foals range from 70 to 80%, while the treatment of infected foals decreases this rate, which persists at 30% ([@B9]; [@B6]). Furthermore, *R. equi* has been reported to frequently infect pigs, and to occasionally infect cattle, cats, and dogs. Although healthy humans are rarely infected with *R. equi*, immunocompromised individuals are susceptible to the infection ([@B34]). Currently, vaccines against rhodococcosis are unavailable commercially, in spite of the significant investment of international resources to develop an effective *R. equi* vaccine ([@B11]).

*Rhodococcus equi* harbors an 80--90-kb plasmid encoding virulence-associated proteins (Vaps) that enable the bacterium to survive, persist, and replicate within the host macrophages ([@B35]). The plasmid comprises of six full-length vap genes (*vapA*, -*C*, -*D*, -*E*, -*G*, and -*H*) and three vap pseudogenes (*vapF*, -*I*, and -*X*), whose coding sequences are either truncated or mutated ([@B9]). All virulent *R. equi* strains isolated from infected foals were reported positive for VapA, a bacterial surface lipoprotein required for intracellular growth in the macrophages. Promisingly, deletion of *vapA* has been shown to attenuate the virulence of *R. equi* strains ([@B14]). Nevertheless, expression of VapA alone is insufficient to facilitate virulence, as demonstrated by [@B8], who studied that the introduction of exogenous wild-type *vapA* into a plasmid-cured *R. equi* strain was not sufficient to restore bacterial virulence, a fact that was demonstrated either in a murine model of *R. equi* infection or in challenged foals. Thus, additional factors are required to facilitate the ability of *R. equi* to colonize tissues and provoke clinical symptoms in foals, as indicated in several studies: (i) [@B26] showed that all vap genes are expressed in *R. equi* isolated from macrophages of infected equines; (ii) [@B18] showed that VapA, VapG, and VapD are present in all the analyzed isolates from clinical samples; (iii) [@B1] demonstrated that the expression of *vapA* and *vapG* can be induced by H~2~O~2~ treatment, suggesting that these genes exert a protective effect against macrophage-related stresses; (iv) [@B13] observed an augmented expression of *vapA, vapD*, and *vapG* in bacteria isolated from the lung tissue of infected foals, suggesting that these genes are implicated in *R. equi* pathogenesis. Together, these results indicate the importance of considering all vap genes as candidates for vaccine components.

Previous studies have demonstrated that the VapA antigen carried by attenuated *Salmonella enterica* Typhimurium (*Salmonella-vapA*+) induces a protective immune response in *R. equi*-challenged mice ([@B20], [@B21]). In the current study, we assessed the ability of the vaccine with VapG-antigen carried by attenuated *S. enterica* Typhimurium (*Salmonella*-*vapG*+) to protect mice against *R. equi* infection.

Materials and Methods {#s1}
=====================

Ethics Statement
----------------

The study was performed according to the norms established by the National Council for the Control of Animal Experimentation (CONCEA). The protocol of the study was approved by the Ethics Committee on Animal Research of the University of São Paulo (USP) (protocol 107/2011).

Mice, Bacterial Strains, and Preparation of Triton X-Extracted Antigen
----------------------------------------------------------------------

Each experimental or control group comprised of five 6--8-week-old female mice of the strains BALB/c, C57BL/6, B cell-deficient (Igh-6^tm1Cgn^), C3H/HeJ, and C3H/HePAS. The animals were housed under pathogen-free conditions in the Animal Research Facilities of the Medical School of Ribeirão Preto, USP. Three independent experiments were carried out to generate a result, except for the construction of the cumulative survival curve, which was performed once.

The *vapG* antigen sequence was synthesized by PCR-amplification of a 519-bp DNA fragment (comprising the *vapG* sequence) from the *R. equi* virulence plasmid (ATCC 33701). Primers (*vapG*-Fw, 5′-GCGGCCGTCGACAAGAGAGGATGATATCATGAGT-3′; *vapG*-Rv, 5′-GCGCGCTGCAGCTATTGCCACCCTCCGGTTC-3′) were used to generate *Sal*I and *Bam*HI restriction sites at either end of the DNA fragment, so as to facilitate directed insertion of *vapG* into the pYA3137 plasmid, as reported by [@B20].

Both the attenuated *S. enterica* Typhimurium 3987 strains \[carrying either *vapG*+, *vapA*+, or the empty vector (control *vapA*-)\] and the virulent strain of *R. equi* (ATCC 33701) were grown and prepared as described by [@B21]. Triton X-extracted antigen (APTX) was prepared as described previously by [@B30].

Immunization and Challenge Protocols
------------------------------------

Mice were orally immunized with attenuated *Salmonella* harboring VapG+ on days 0 and 14 of the experiment as described previously by [@B20]. PBS and *Salmonella* carrying empty vector were orally administrated to the negative control mice. Challenges with *R. equi* were conducted by administrating inoculum of the virulent *R. equi* strain ATCC 33701 at a sub-lethal dose, 30 days after the first immunization. Organs were harvested 5 days after the challenge with *R. equi*.

The curve of the cumulative mice survival was constructed by using the Kaplan-Meier method ([@B15]). Thirty days after immunization with a single oral vaccine, mice were challenged with a lethal *R. equi* inoculum. Mortality was recorded daily during the 15-day period after the challenge.

Quantification of Bacterial Burden in Organs of *R. equi*-Challenged Mice
-------------------------------------------------------------------------

Quantification of viable *R. equi* recovered from the spleen and liver of the challenged mice was performed as previously described ([@B20]). Briefly, 30 days after the first immunization, mice were infected intravenously with 4 × 10^6^ colony forming units (CFUs) of virulent *R. equi*. Five days after the challenge, the spleen and liver from the mice were harvested and aseptically homogenized. Samples (100 μL each) of the homogenates were diluted in sterile PBS, plated onto BHI agar in duplicates, and incubated at 37°C for 36 h before CFU counting.

Cytokine Determination
----------------------

Samples of the spleen homogenates obtained 30 days after the first immunization or 5 days after *R. equi* challenge were assessed for IL- 12p70, IFN-γ, and TNF-α levels by ELISA, using an OptEIA kit (BD Pharmingen, San Diego, CA, USA) according to the manufacturer's instructions.

Flow Cytometry Analysis
-----------------------

The spleen cells (1 × 10^7^) from immunized and control mice were harvested 15 days post-immunization, washed with ice-cold PBS, and incubated (30 min, 4°C) with anti-CD16/CD32 mAb (Fc block, clone 2.4G2, BD Pharmingen). After centrifugation and washing, the cells were incubated with anti-CD19, anti-CD3, anti-CD4, and anti-CD8 (PE- or FITC-labeled; BD Pharmingen) for 40 min. Washing was performed using PBS with 0.5% BSA, and the cells were analyzed using a Guava flow cytometer and CytoSoft version 4.2.1 software (Millipore, Billerica, MA, USA).

Detection of Anti-*R. equi* Specific Antibodies in Mice Serum
-------------------------------------------------------------

Blood samples were collected from mice (*n* = 4) on days 0 and 30 after the first immunization. Serum anti-*R. equi* antibodies were titrated by ELISA in APTX- (primarily constituted of VapA as demonstrated by [@B25]) or recombinant VapG-coated microtiter plates (Costar, USA) prepared as described previously by [@B19] (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). Samples were diluted 1:120 in PBS containing 0.05% Tween-20 for the detection of anti-APTX IgG, and serially (log~2~) for the titration of anti-VapG IgG. Reactions were detected using goat anti-mouse IgG conjugated with horseradish-peroxidase (1:5000, Santa Cruz Biotechnology).

Statistical Analyses
--------------------

Statistical analysis was performed using GraphPad Prism 6 software. Comparison of data between the two groups was performed by Student's *t*-test. Data from three or more groups were compared by one-way analysis of variance (ANOVA) followed by Tukey's test. The index of mice survival for each group was analyzed by Log-rank test ([@B22]).

Results
=======

Immunization with VapG+ Carried by Attenuated *Salmonella* Protects Mice against *R. equi* Infection
----------------------------------------------------------------------------------------------------

It was previously demonstrated that oral immunization of mice with *Salmonella*-*vapA*+ confers resistance toward *R. equi* infection ([@B20], [@B21]; [@B3]). Because VapG antigen, similar to VapA, is encoded by a gene of the *R. equi* virulence plasmid and is highly expressed in the lung tissue of *R. equi*-infected foals ([@B6]), in this study, we evaluated the effect of *Salmonella*-*vapG*+ vaccination in mice. A significant reduction in the bacterial burden in the spleen and liver, the *R. equi*-targeted organs, was detected in the vaccinated mice challenged with a *R. equi* inoculum at a sub-lethal dose as compared to that detected in the unvaccinated mice (**Figures [1A,B](#F1){ref-type="fig"}**). Interestingly, the observed CFU reduction in *Salmonella*-*vapG*+-immunized mice was comparable to that previously observed in *Salmonella*-*vapA*+-immunized mice ([@B20]). Furthermore, in this study, the protective effect of the Toll-like Receptor 4 (TLR4) activation due to the *Salmonella* carrier occurred in an independent manner, since the results in the TLR4-deficient mice were similar to those in the WT mice (**Figures [1C,D](#F1){ref-type="fig"}**). When challenged with a lethal dose of *R. equi*, 50% of the *Salmonella*-*vapG*+-immunized mice survived, whereas all non-immunized control mice, who received PBS or the empty vector instead of the vaccine, died within 1 week after the challenge. Mice immunized with APTX, which induces a strong anti-VapA humoral response ([@B25]), died within 10 days after the challenge (**Figure [1E](#F1){ref-type="fig"}**).

![**Vaccination with attenuated *Salmonella enterica* Typhimurium carrying VapG antigen induces protection against *Rhodococcus equi* challenge in mice.** Mice were orally immunized on days 0 and 14 with either *S. enterica* Typhimurium χ3987-pYA3137 (Control), χ3987-pYA3137*vapG* (VapG+), χ3987-pYA3137*vapA* (VapA+), PBS, or APTX (with Freund's adjuvant). Thirty days after the first immunization, mice were challenged with *R. equi* (ATCC33701 strain), before being sacrificed 5 days post-infection. The *R. equi* burden was evaluated in the spleen and liver of **(A,B)** BALB/c, and **(C,D)** C3H/HePAS and C3H/HeJ mice. **(E)** A cumulative survival curve was constructed for *R. equi*-challenged BALB/c mice following immunization with PBS (circles), VapG+ (triangles), or APTX (squares). Data are represented as mean ± SE, ^∗^*p* \< 0.05 (Tukey's test).](fmicb-08-00857-g001){#F1}

*Salmonella*-*vapG*+ Vaccination Elicits Interferon-Gamma Responses in Mice
---------------------------------------------------------------------------

To evaluate the association between the protection conferred by *Salmonella*-*vapG*+ vaccination and a cytokine response, the content of Th1-type cytokines (i.e., IL-12, IFN-γ, and TNF-α) in the spleen of vaccinated and *R. equi*-challenged mice was assessed. The spleen homogenates from *Salmonella*-*vapG*+-immunized mice exhibited a higher IL-12 and IFN-γ content than that in the spleen homogenates from mice in the control group, before or after the *R. equi* challenge (**Figures [2A--D](#F2){ref-type="fig"}**). The TNF-α content in the spleen was also augmented following *Salmonella*-*vapG*+ vaccination (**Figure [2E](#F2){ref-type="fig"}**). However, the TNF-α content decreased when the immunized mice were challenged with *R. equi*, reaching to levels comparable to those in the mice from the negative control group (**Figure [2F](#F2){ref-type="fig"}**). Notably, the control group vaccinated with the empty vector (*Salmonella-vapA*-) augmented the TNF-α content in the spleen significantly, and this result was consistent with that of the previous studies ([@B21]; [@B3]).

![**Vaccination with attenuated *S. enterica* Typhimurium carrying VapG antigen elicits a Th1 immune response.** Mice were orally immunized on days 0 and 14 with *S. enterica* Typhimurium χ3987-pYA3137 (Control), χ3987-pYA3137*vapG* (VapG+), or PBS. Thirty days after the first immunization, mice were challenged with *R. equi* (ATCC33701 strain), before being sacrificed 5 days post-infection. The cytokines **(A,B)** IL12p70, **(C,D)** IFN-γ, and **(E,F)** TNF-α were evaluated by ELISA using the spleen homogenates. Data are represented as mean ± SE, *n* = 5 mice/treatment group, ^∗^*p* \< 0.05 (Tukey's test).](fmicb-08-00857-g002){#F2}

*Salmonella*-*vapG*+ Vaccination Increases B-Cell Populations in the Spleen and Induces a Protective Humoral Response in Mice
-----------------------------------------------------------------------------------------------------------------------------

To determine the effect of *Salmonella*-*vapG*+ vaccination on the lymphocyte proliferation, the frequency of CD19+, CD3+CD4+, and CD3+CD8+ cells was compared in spleen homogenates from immunized and control group mice. The flow cytometric analysis showed that as compared to mice in the PBS- or *Salmonella*-*vapA*--control groups, *Salmonella*-*vapG*+-immunized mice displayed an increased frequency of B cells (**Figure [3A](#F3){ref-type="fig"}**), whereas the incidence of T cells was similar among the groups (**Figures [3B,C](#F3){ref-type="fig"}**).

![**Vaccination with attenuated *S. enterica* Typhimurium carrying VapG antigen increases B cell frequency.** BALB/c mice were orally immunized on days 0 and 14 with *S. enterica* Typhimurium χ3987-pYA3137 (Control), χ3987-pYA3137*vapG* (VapG+), or PBS. Thirty days after the first immunization, mice were sacrificed, and the frequency of splenic **(A)** CD3+ and CD19+, **(B)** CD3+CD4+, and **(C)** CD3+CD8+ cells was evaluated. Data represent the mean ± SE, *n* = 5 mice/treatment group, ^∗^*p* \< 0.05 (Tukey's test).](fmicb-08-00857-g003){#F3}

To evaluate the specific antibodies secreted due to *Salmonella*-*vapG*+ vaccination, serum titration was performed using recombinant VapG-coated microplates. As shown in **Figure [4A](#F4){ref-type="fig"}**, the serum IgG of the *Salmonella*-*vapG*+-vaccinated mice reacted with the recombinant VapG, showing absorbance readings four-times higher than those obtained by reacting with serum IgG from negative controls, up to a dilution of 1:960.

![**Vaccination with attenuated *S. enterica* Typhimurium carrying VapG antigen induces antibodies critical to the protective immune response.** BALB/c mice were orally immunized on days 0 and 14 with *S. enterica* Typhimurium χ3987-pYA3137 (Control), χ3987-pYA3137*vapA* (VapA+), χ3987-pYA3137*vapG* (VapG+), or PBS. Serum was collected 30 days after the first immunization, and used to measure **(A)** VapG- or **(B)** APTX-specific IgG by ELISA. C57BL/6 BKO and C57BL/6 WT mice were orally immunized on days 0 and 14 with *S. enterica* Typhimurium χ3987-pYA3137*vapG* (VapG+) or PBS. Thirty days after the first immunization, mice were challenged with *R. equi* (ATCC 33701 strain), before being sacrificed 5 days post-infection. The *R. equi* burden was evaluated in the **(C)** spleen (CFU/g) and **(D)** lung. Data represent the mean ± SE, ^∗^*p* \< 0.05 (Tukey's test).](fmicb-08-00857-g004){#F4}

It was previously reported that Vap proteins display high homology in their C-terminus regions ([@B29]); therefore, the cross-reactivity of serum IgG from the *Salmonella*-*vapG*+-vaccinated mice with recombinant VapA antigen, contained in the APTX preparation used to coat a second set of microplates, was assessed. For this analysis, the serum samples were used at a dilution of 1:120, and serum from *Salmonella*-*vapA*+-immunized mice served as the positive control. Only this positive control serum reacted with the APTX coating (**Figure [4B](#F4){ref-type="fig"}**), which was not recognized by the serum IgG of the *Salmonella*-*vapG*+-vaccinated mice. This suggests that the vaccine induced generation of VapG-specific IgG antibodies, which account for the protective humoral response against *R. equi* infection as studied in the vaccinated mice.

To address the relevance of the elicited antibody response for protection against *R. equi* infection conferred by *Salmonella*-*vapG*+ vaccination, B-cell deficient mice (B-cell KO) were immunized ([@B16]). PBS, instead *Salmonella*-*vapG*+, was administered in the negative control mice. The *Salmonella*-*vapG*+-vaccinated B-cell KO mice, as well as the negative control mice, were not protected against the *R. equi* challenge, as demonstrated by a similar bacterial burden displayed by all the groups of mice (**Figures [4C,D](#F4){ref-type="fig"}**). Thus, the generation of VapG-specific antibodies is crucial for the protective effect against *R. equi* conferred by *Salmonella*-*vapG*+ vaccination in mice.

Discussion
==========

For several years, vaccines containing the bacterial virulence antigen VapA (encoded by an 85-kb plasmid) were considered as the most promising strategy to prevent rhodococcosis. However, this strategy has been unsuccessful until now owing to the complexity of *R. equi* virulence, as observed in previous studies performed using different strategies in immunized horses---virulence plasmid-cured *R. equi* strain ([@B8]), inactivated *R. equi* strain ([@B31]; [@B2]), or VapA associated to other antigens ([@B5]). Some strategies, such as using a DNA vaccine ([@B23]) or virulence plasmid-negative *R. equi* strain expressing *vapA* ([@B33]), were unsuccessful even in mouse models. [@B6], by using a *vapG*-mutant strain, reported that VapG plays a major role in *R. equi* virulence. Nevertheless, the efficacy of VapG as an *R. equi* vaccine candidate has not yet been tested.

In the present study, we assessed VapG as a *Salmonella*-based live-vector vaccine, an approach that was previously efficient in delivering VapA ([@B20], [@B21]; [@B3]). Vaccination with *Salmonella*-*vapG*+ significantly reduced the bacterial burden exhibited by *R. equi*-challenged mice. However, among the mice challenged with a lethal dose of *R. equi* inoculum, only 50% of the *Salmonella*-*vapG*+-vaccinated mice survived, while 100% survival rate was reported for *Salmonella*-*vapA*+-vaccinated mice ([@B20]). Vaccination with either *Salmonella*-*vapG*+ or *Salmonella*-*vapA*+ was associated with a significant increase in IL-12 and IFN-γ production in response to *R. equi* infection, whereas the TNF-α levels produced in *Salmonella*-*vapA*+- or *vapG*+-vaccinated mice were as low as those in the negative control mice. Immunization with *Salmonella*-*vapG*+ caused an increase in the splenic B-cell population, whereas the frequency of CD4+ and CD8+ T cells did not vary amongst the groups. This result contrasts previously reported findings for *Salmonella*-*vapA*+-vaccinated mice ([@B21]) that exhibited a significant increase in T-cell populations. Our observations suggested that the *Salmonella*-*vapG*+ vaccine elicits a protective humoral immune response, but not a cellular immune response, a fact that may explain the modest survival rate among the *Salmonella*-*vapG*+-vaccinated mice that were challenged with a lethal dose of *R. equi* inoculum. The *Salmonella*-*vapG*+-vaccinated mice were shown to produce specific antibodies that account for a partial protection against *R. equi* infection, a hypothesis that is supported by the failure of the *Salmonella*-*vapG*+ vaccine in protecting B-cell KO mice against *R. equi* infection.

It is accepted that VapA+ is a fundamental component of any effective *R. equi* vaccine because it elicits a robust Th1 cellular immune response, which is essential for fighting against the bacteria. Simultaneously, the humoral immune response elicited by VapA seems inefficient to protect the challenged mice ([@B25]). Our present study demonstrates that VapG+ elicits a specific humoral immune response, and makes the relevance of this response evident in conferring partial protection against *R. equi* infection. Then, we postulate that a vaccine against *R. equi* would be more efficient by associating various Vap antigens. The combined delivery of VapA and VapG antigens may result in protective responses owing to the stimulation of both axes of immunity---the cellular axis by VapA and the humoral axis by VapG. Presumably, the double efficient stimuli would provide an advantageous vaccination strategy, increasing the chances of reproducibility in foals similar to that obtained in mouse models. Nonetheless, we must highlight that several vaccination strategies that were successful in laboratory experimental animals failed in animals of the target (equine) species, as previously demonstrated with unsuccessful immunization of foals with VapA ([@B24]; [@B17]), a formulation that had proved protective in mice ([@B25]; [@B12]). Because prevention and treatment of rhodococcosis in foals is frequently carried out by passive immunization, achieved by the administration of hyperimmune plasma (HIP) or vaccination of pregnant mares, we proposed to include VapG, rather than VapA, in the immunogenic preparations used to induce formation of specific antibodies to be transferred to foals. Various commercial HIPs contain several different subclasses of immunoglobulins that are specific to VapA+ or components of inactivated virulent *R. equi*. Although the administration of the commercial HIPs has been reported to be associated mild pneumonia following *R. equi* challenge ([@B27]), their efficacy is still controversy ([@B7]; [@B4]; [@B28]). Commercial HIPs elicit a variable range of responses, probably due to the presence of several Ig isotypes with specificities toward numerous antigens used in the immunization procedure. The use of VapG as an immunogen may provide an approach to improve the efficacy of the treatment with HIP of *R. equi*. Briefly, we are trying to offer a rational basis for VapG addition in future vaccines against rhodococcosis and to make passive immunization of foals more efficient.

Conclusion
==========

The results of the present study allow us to propose VapG as an appropriate antigen for the development of vaccines and treatment against *R. equi* infection. This hypothesis is based on the ability of VapG to elicit a robust humoral immune response that can confer partial protection to *R. equi*-challenged mice. Further investigation is required to select the ideal delivery of VapA and VapG antigens in a single vaccine, and study the cellular and humoral responses elicited by the vaccine in newborn foals exposed to *R. equi* infection.
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